PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Neoplasms
- First Posted Date
- 2002-12-24
- Last Posted Date
- 2006-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 163
- Registration Number
- NCT00050830
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support
Phase 3
Completed
- Conditions
- Pneumonia
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT00050401
Treatment of Pediatric Hypertension With Altace Trial
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2002-08-26
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 310
- Registration Number
- NCT00044265
- Locations
- 🇺🇸
Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸PCTI at Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Breast
- Interventions
- Drug: 0.08 mg/kg CpG 7909Drug: 0.04 mg/kg CpG 7909Drug: 0.12 mg/kg CpG 7909Drug: 0.16 mg/kg CpG 7909
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00043394
- Locations
- 🇺🇸
Pfizer Investigational Site, Burlington, Vermont, United States
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Phase 2
Completed
- Conditions
- MelanomaBreast NeoplasmsCarcinoma, Renal CellLymphoma, T-CellCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00043368
- Locations
- 🇩🇪
Pfizer Investigational Site, Koeln, Germany
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: CPG 7909
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00043407
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00043420
The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)
Phase 2
Completed
- Conditions
- Candidiasis
- First Posted Date
- 2002-07-16
- Last Posted Date
- 2008-10-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT00041704
- Locations
- 🇺🇸
Versicor, Inc., King of Prussia, Pennsylvania, United States
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women
Phase 2
Terminated
- Conditions
- Breast Neoplasms
- First Posted Date
- 2002-06-20
- Last Posted Date
- 2012-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00040014
- Locations
- 🇬🇧
Pfizer Investigational Site, Leicester, United Kingdom
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Phase 3
Completed
- Conditions
- Non-Hodgkin LymphomaHodgkin DiseaseThrombocytopenia
- First Posted Date
- 2002-06-17
- Last Posted Date
- 2007-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT00039910
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
© Copyright 2025. All Rights Reserved by MedPath